Your comparisons are meaningless, as FY14 is history and almost a different company. MCP has divested under-performing businesses and stock lines, moving to higher quality growth items such as new lines in health and beauty products, hence reducing revenue. Underlying earnings per share is up around 10% and EBIT is up around 14% on much lower revenues. That is a quality result which should continue in FY17.
Your comparisons are meaningless, as FY14 is history and almost...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.10M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 106827 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 33000 | 2 |
View Market Depth
| Last trade - 07.18am 18/06/2025 (20 minute delay) ? |
| MCP (ASX) Chart |
Day chart unavailable